Pharminent

Roche Forms Global Immunotherapy R&D Network

NewsRoche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations related to cancer immunotherapy.Topics: Biotech http://www.dddmag.com/news/2016/11/roche-forms-global-immunotherapy-r-d-network

Filed under: Cancer, Immunotherapy

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment met its primary endpoint, improving ACR20 response at week 16 versus placebo in patients suffering from active psoriatic arthritis.
read more http://www.pharmafile.com/news/511386/celgenes-otezla-hits-primary-endpoint-psoriatic-arthritis-study

Filed under: Arthritis

Kite details filing plans for lead CAR-T

If all goes according to plan, Kite’s KTE-C19 could be the first CAR-T approved in the U.S. http://www.biopharmadive.com/news/kite-cart-kte-c19-filing-fda/430147/

Filed under: Cancer, Immunotherapy

Study Challenges Model of Alzheimer’s Disease Progression

NewsAlzheimer’s disease is a neurodegenerative disorder for which, despite years of research, there are no effective treatments or cures.Contributed Author: Cornell UniversityTopics: Disease Research http://www.dddmag.com/news/2016/11/study-challenges-model-alzheimers-disease-progression

Filed under: Alzheimer’s

Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026

LONDON, Nov. 7, 2016 /PRNewswire/ — Report DetailsMS Drugs – Discover R&D Trends and Markets with Highest Revenue PotentialsWhere is the multiple sclerosis drugs market heading? Visiongain’s new study predicts that pharma industry’s revenues from 2016. There you find potentials for… http://www.prnewswire.com/news-releases/multiple-sclerosis-drugs-market-and-rd-outlook-2016-2026-300358877.html

Filed under: MS

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for
long-term use, post-heart attack http://www.pmlive.com/pharma_news/nice_backed_expanded_use_of_brilique_in_final_guidance_1175654

Filed under: Cardiovascular

FDA delays approval of Sanofi and Regeneron’s rheumatoid arthritis drug sarilumab

The US Food and Drug Administration (FDA) has delayed approval for Sanofi and Regeneron Pharmaceuticals’ experimental treatment for rheumatoid arthritis (RA) due to manufacturing deficiencies. http://manufacturing.pharmaceutical-business-review.com/news/setback-for-sanofi-and-regeneron-as-fda-delays-ra-drug-approval-311016-5652570

Filed under: Arthritis

Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness

http://www.fiercepharma.com/pharma/amgen-bids-farewell-to-enbrel-price-hikes-and-big-sales-boosts-they-brought

Filed under: Pricing

Asthma Research Yields New Treatment Approach for Inherited Enzyme Disease

NewsThe study results address Gaucher’s disease.Contributed Author: NYU Langone Medical CenterTopics: Disease Research http://www.dddmag.com/news/2016/10/asthma-research-yields-new-treatment-approach-inherited-enzyme-disease

Filed under: Respiratory

Novartis explains why it canned the cell therapy unit

The Swiss pharma talked about its reasons for re-absorbing its Cell & Gene Therapies unit during a call with investors.  http://www.biopharmadive.com/news/novartis-explains-why-it-canned-the-cell-therapy-unit/429024/

Filed under: Company

Myriad RBM, Sanofi Partner to Identify CV Biomarkers in Diabetes Patients

https://www.genomeweb.com/molecular-diagnostics/myriad-rbm-sanofi-partner-identify-cv-biomarkers-diabetes-patients

Filed under: Diabetes

MSD’s Keytruda given first FDA approval for first line treatment

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with the FDA approving Keytruda for first-line treatment for the first time. This means that Keytruda will be the first treatment for patients with metastatic NSCLC with high-levels of the protein, PD-L1, that is known for suppressing the immune system.
read more http://www.pharmafile.com/news/511081/msd-s-keytruda-given-first-fda-approval-first-line-treatment

Filed under: Cancer, Immunotherapy

CardioBrief: Eliquis Nipping At Heels of Top-Selling NOAC Xarelto

(MedPage Today) — Overall market for the new oral anticoagulants continues to expand http://www.medpagetoday.com/Cardiology/CardioBrief/60945

Filed under: Cardiovascular

Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials

A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease. http://clinicaltrials.pharmaceutical-business-review.com/news/theravance-and-mylans-copd-treatment-shows-benefits-in-phase-3-trials-211016-5039060

Filed under: COPD

Roche creates the Fight IPF choir for disease awareness campaign

Aims to raise the lung disease’s profile and
inform patients and their families http://www.pmlive.com/pharma_news/roche_creates_the_fight_ipf_choir_for_disease_awareness_campaign_1172955

Filed under: Marketing

Elsevier’s R&D Solutions Welcomes Four Biotech Start-Ups to the Hive

NEW YORK, October 20, 2016 /PRNewswire/ — Incubator Participants Receive Complimentary Access to Elsevier’s Information Solutions to Accelerate Research in Early Drug Discovery and Development Elsevier, a world-leading provider of scientific, technical and medical… http://www.prnewswire.com/news-releases/elseviers-rd-solutions-welcomes-four-biotech-start-ups-to-the-hive-597725141.html

Filed under: R&D

Roche in “unprecedented” launch period for new medicines

Cotellic, Alecensa, Venclexta and Tecentriq position firm to meet 2016 sales targets http://www.pmlive.com/pharma_news/roche_in_unprecedented_launch_period_for_new_medicines_1172187

Filed under: Company

Pfizer anchoring inflammation hopes in Xeljanz

After a slow launch, the RA drug is picking up speed, leading the big pharma to invest in growing it further.  http://www.biopharmadive.com/news/pfizer-anchoring-inflammation-hopes-in-xeljanz/428643/

Filed under: Arthritis

The Power of the Cloud for Life Science R&D

“In the new world, it is not the big fish which eats the small fish, it’s the fast fish which eats the slow fish…” — Klaus Schwab, Founder/Executive Chairman, World Economic Forum Over the past decade, the nature of innovation has changed—even as the pace has substantially increased. One of the reasons has been the ability […] http://www.xconomy.com/boston/2016/10/19/the-power-of-the-cloud-for-life-science-rd/

Filed under: R&D

Roche’s immunotherapy cancer drug given FDA approval

Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given FDA approval for treatment of metastatic non-small cell lung cancer. The figures released earlier this month showed that those taking the drug lived a median of 13.8 months, which worked out, on average, as 4.2 months longer than those being treated with chemotherapy.
read more http://www.pharmafile.com/news/510795/roche-s-immunotherapy-cancer-drug-given-fda-approval

Filed under: Cancer, Immunotherapy

Categories